Arbour Paola M

EVP/CIO Paola M Arbour sold 6,500 THC shares at $238.43 on 2026-03-11 ($1.5M); holds 29.3K shares remaining.

Arbour sold 6,500 shares (a reduction of 18.2% from pre-transaction holdings of 35.8K shares) at $238.43, which was 4.7% above the current price of $227.63 and near the 52-week high of $244.80. At the 90-day mark, her prior five sales at this ticker have produced an average return of +9.6%, with 0 of 5 showing negative returns—indicating she has historically sold ahead of appreciation rather than ahead of declines. Her cross-ticker track record shows 0.00% well-timed rate on 6 prior sells (avg 90d return +10.4%), suggesting limited predictive timing skill overall. The company trades at a P/E of 33.09 with recent quarterly revenue of $5.3B and net income of $579.0M (annual growth +3.1%), fundamentals that do not signal distress. The transaction appears discretionary and falls within routine insider rebalancing of a large holding.

Director Paola M Arbour buys 1,000 shares of TCBI at $91.50; holdings rise 17.6% to 6,671 shares.

Director Paola M Arbour purchased 1,000 shares of TEXAS CAPITAL BANCSHARES INC/TX at $91.50, increasing her holdings by 17.6% from 5,671 to 6,671 shares. The transaction occurred when the stock is trading -12.9% from its 52-week high of $105.98 and down -11.2% over the prior 30 days, suggesting the purchase came during a period of weakness. However, the company faces headwinds: annual revenue contracted -37.4% year-over-year, raising questions about underlying business fundamentals despite a low P/E of 7.37. Against this mixed context—depressed price action and deteriorating top-line growth—the director's open-market purchase warrants monitoring for signal reliability, given her prior cross-ticker sells have posted a 0.00% well-timed rate (90-day returns after prior sells averaged +10.4%, indicating her historical sell exits were poorly timed).

Paola M Arbour (EVP/CIO) sells 7,738 shares of THC at $173.00; holds 20,110 shares post-transaction.

Arbour sold 7,738 shares (27.8% of pre-transaction holdings) at $173.00 on 2025-06-05, reducing her stake to 20,110 shares. The sale occurred at a price only 0.2% below the 52-week high of $171.84, and the stock has advanced 12.6% over the prior 30 days and 34.5% over 90 days. Her prior 4 measurable sells at THC all returned positive 90-day gains (ranging +2.8% to +36.4%), suggesting a pattern of selling into strength rather than ahead of declines; none of those four prior sales was well-timed in the directional sense. Given the stock's strong recent momentum and valuation metrics (P/E 6.77, market cap $15.9B), this sale represents a reduction of position concentration following a sustained rally rather than a signal of deterioration.

CIO Paola M. Arbour sold 6,461 shares of THC at $160.20 (May 15, 2025) amid stock surge; prior sells at this ticker unprofitable at 90d horizon

Arbour sold 6,461 shares (18.8% of her pre-transaction holdings) at $160.20 during a pronounced upward phase: the stock has risen 37.4% over the past 30 days and 24.1% over 90 days, now trading at $165.47. The sale timing contrasts sharply with her track record at THC specifically—her four prior sales at this ticker all resulted in positive 90-day returns (ranging from +4.1% to +36.4%), meaning the stock rose after each sale, with zero well-timed sales at the 90-day mark. At the company level, fundamentals remain modest: THC trades at a P/E of 6.54 with annual revenue growth of only 0.6%, though net income of $622.0M on $5.2B in quarterly revenue suggests operational profitability. The pattern suggests this sale may not reflect anticipated weakness; rather, it extends a historical tendency for her THC sales to precede continued gains, raising a question about whether the magnitude and velocity of the recent rally influenced a liquidity or portfolio decision rather than a conviction-driven exit.

CIO Paola M Arbour sells 8,377 THC shares at $156.00; holds 21,426 post-sale. Stock -0.9% from 52-week high.

Arbour Paola M, EVP and Chief Information Officer, sold 8,377 shares of Tenet Healthcare on 2024-08-16 at $156.00, reducing her holdings by 28.1% from 29,803 to 21,426 shares. The transaction occurred near the stock's 52-week high ($156.66), with the stock currently trading at $155.22 and up 16.5% over the preceding 30 days and 19.0% over 90 days. Her prior three sales at THC generated 90-day returns of +36.4%, +2.8%, and +3.3%—none of which were well-timed (all posted positive returns, meaning the stock rose after the sale). Tenet's fundamentals show strong growth (7.2% annual revenue growth, $5.1B quarterly revenue, $477.0M net income) and a notably low P/E of 4.21, which may reflect market pricing of the healthcare sector or company-specific factors.